Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection

J Zuo, A Dowell, H Pearce, K Verma, HM Long, J Begum, F Aiano, Z Amin-Chowdhury, B Hallis, L Stapley, R Borrow, E Linley, S Ahmad, B Parker, A Horsley, G Amirthalingam, K Brown, ME Ramsay, S Ladhani, P Moss
doi: https://doi.org/10.1101/2020.11.01.362319
J Zuo
1Institute of Immunology and Immunotherapy, University of Birmingham, UK. B15 2TA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Dowell
1Institute of Immunology and Immunotherapy, University of Birmingham, UK. B15 2TA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H Pearce
1Institute of Immunology and Immunotherapy, University of Birmingham, UK. B15 2TA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K Verma
1Institute of Immunology and Immunotherapy, University of Birmingham, UK. B15 2TA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HM Long
1Institute of Immunology and Immunotherapy, University of Birmingham, UK. B15 2TA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Begum
1Institute of Immunology and Immunotherapy, University of Birmingham, UK. B15 2TA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F Aiano
2Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Z Amin-Chowdhury
2Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B Hallis
3Immunoassay Lab, National Infection Service, Porton Down SP4 0JG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L Stapley
3Immunoassay Lab, National Infection Service, Porton Down SP4 0JG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Borrow
4Sero-epidemiology Unit, Public Health England, Public Health Laboratory Manchester, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E Linley
4Sero-epidemiology Unit, Public Health England, Public Health Laboratory Manchester, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Ahmad
5The NIHR Manchester Clinical Research Facility at Wythenshawe Hospital, Charles Blackley Ward, North West Lung Research Centre, Manchester University NHS Foundation Trust, Wythenshawe Hospital, South moor Road, Manchester, M23 9LT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B Parker
6NIHR Manchester Clinical Research Facility, Manchester Royal Infirmary, Oxford Rd, Manchester, M13 9WL & Kellgren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, M13 9WL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Horsley
7University of Manchester and NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester M23 9LT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Amirthalingam
2Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K Brown
2Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ME Ramsay
2Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Ladhani
2Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ
8Paediatric Infectious Diseases Research Group (PIDRG), St. Georges University of London, (SGUL), London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Moss
1Institute of Immunology and Immunotherapy, University of Birmingham, UK. B15 2TA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: p.moss@bham.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

The immune response to SARS-CoV-2 is critical in both controlling primary infection and preventing re-infection. However, there is concern that immune responses following natural infection may not be sustained and that this may predispose to recurrent infection. We analysed the magnitude and phenotype of the SARS-CoV-2 cellular immune response in 100 donors at six months following primary infection and related this to the profile of antibody level against spike, nucleoprotein and RBD over the previous six months. T-cell immune responses to SARS-CoV-2 were present by ELISPOT and/or ICS analysis in all donors and are characterised by predominant CD4+ T cell responses with strong IL-2 cytokine expression. Median T-cell responses were 50% higher in donors who had experienced an initial symptomatic infection indicating that the severity of primary infection establishes a ‘setpoint’ for cellular immunity that lasts for at least 6 months. The T-cell responses to both spike and nucleoprotein/membrane proteins were strongly correlated with the peak antibody level against each protein. The rate of decline in antibody level varied between individuals and higher levels of nucleoprotein-specific T cells were associated with preservation of NP-specific antibody level although no such correlation was observed in relation to spike-specific responses. In conclusion, our data are reassuring that functional SARS-CoV-2-specific T-cell responses are retained at six months following infection although the magnitude of this response is related to the clinical features of primary infection.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted November 02, 2020.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection
J Zuo, A Dowell, H Pearce, K Verma, HM Long, J Begum, F Aiano, Z Amin-Chowdhury, B Hallis, L Stapley, R Borrow, E Linley, S Ahmad, B Parker, A Horsley, G Amirthalingam, K Brown, ME Ramsay, S Ladhani, P Moss
bioRxiv 2020.11.01.362319; doi: https://doi.org/10.1101/2020.11.01.362319
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection
J Zuo, A Dowell, H Pearce, K Verma, HM Long, J Begum, F Aiano, Z Amin-Chowdhury, B Hallis, L Stapley, R Borrow, E Linley, S Ahmad, B Parker, A Horsley, G Amirthalingam, K Brown, ME Ramsay, S Ladhani, P Moss
bioRxiv 2020.11.01.362319; doi: https://doi.org/10.1101/2020.11.01.362319

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Immunology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4246)
  • Biochemistry (9176)
  • Bioengineering (6807)
  • Bioinformatics (24069)
  • Biophysics (12161)
  • Cancer Biology (9568)
  • Cell Biology (13847)
  • Clinical Trials (138)
  • Developmental Biology (7662)
  • Ecology (11739)
  • Epidemiology (2066)
  • Evolutionary Biology (15547)
  • Genetics (10673)
  • Genomics (14366)
  • Immunology (9517)
  • Microbiology (22916)
  • Molecular Biology (9135)
  • Neuroscience (49170)
  • Paleontology (358)
  • Pathology (1488)
  • Pharmacology and Toxicology (2584)
  • Physiology (3851)
  • Plant Biology (8353)
  • Scientific Communication and Education (1473)
  • Synthetic Biology (2302)
  • Systems Biology (6207)
  • Zoology (1304)